A former federal AI regulator who has since moved into the biopharma sector is raising questions about how the pharmaceutical industry is reading official guidance on artificial intelligence from the Food and Drug Administration.
Tala Fakhouri, who previously worked on AI regulation at the FDA, contends that companies across the biopharma landscape are interpreting the agency's AI-related guidance with an excess of caution — a stance that, in her view, does not accurately reflect what the framework actually requires.
"Companies are being too conservative in how they interpret FDA's AI guidance, but the agency can do more to help, too." — Tala Fakhouri
A Two-Sided Problem
According to reporting by STAT News, Fakhouri does not place the burden of misinterpretation solely on industry. She also argues that the FDA itself could take additional steps to help companies arrive at a more accurate reading of its guidance. In her view, the current situation reflects a gap between what the agency has communicated and what regulated entities have understood.
The position is notable given Fakhouri's background. Having worked inside the regulatory apparatus before transitioning to the industry side, she occupies an unusual vantage point — familiar with both the intent behind the guidance and the practical pressures companies face when applying it.
Regulatory Caution and Its Costs
Overly conservative interpretations of regulatory guidance are not uncommon in highly scrutinised sectors. When companies are uncertain about how a framework applies to a novel technology, the default tendency is often to err on the side of restriction. In the context of AI — a rapidly evolving field where regulatory norms are still taking shape — that tendency may be especially pronounced.
Fakhouri's argument implies that this conservatism, while understandable, may be creating unnecessary friction in the development and deployment of AI tools within biopharma. At the same time, her acknowledgment that the FDA could provide clearer direction suggests the issue is not straightforwardly one of industry overcaution alone.
Broader Context
The FDA has been developing its approach to AI in drug development and regulatory submissions over recent years, issuing guidance documents intended to clarify expectations for companies using these technologies. The degree to which that guidance has been successfully communicated — and correctly received — remains an open question, one that Fakhouri's perspective brings into sharper focus.
The remarks add a practitioner's dimension to ongoing discussions about how regulatory bodies and the industries they oversee can better align on the application of emerging technology standards.